Pathological staging of lung cancer

pathological staging remains a definitive suggests that of quantifying
extent of disease. staging considerations differ for non–small
cell carcinoma and tiny cell carcinoma and are discussed
separately.
staging of non–small cell carcinoma revised
staging definitions for nsclc have recently been compiled
by the iaslc and are summarized in table 22. five. this revision
is that the results of an international effort involving forty six data
sources from nineteen countries that began in 1996. 394–398 data
from 67, 725 nsclc patients with 5-year follow-up and complete
staging data were analyzed to arrive at the ultimate
revision. changes created within the staging system embrace refinement
of the t-stage criteria, revision of the classification of
intrapulmonary multifocal tumor, and stratification of the m
class as follows :
one. analysis of t1 tumors indicated separation of kaplan-
meier survival curves for tumors but two cm (median
survival 103 months) versus tumors between two and three cm
(median survival 124 months). to accommodate this distinction,
the t stages 1a and 1b were introduced.
two. analysis of outcome information prompted the reclassification of
tumors with separate nodules within the same lobe from the t4
to t3, those with nodules in separate ipsilateral lobes as t4
and people with nodules within the contralateral lung as m1.
three. m1 disease was subdivided into an m1a class that consists
of intrathoracic metastases to the contralateral lung or
to either pleura and an m1b class that includes distant
metastasis.
details of the changes that are incorporated into the new
staging theme are provided elsewhere. 394–398
a crucial element of staging is that the assessment
of pleural invasion. assessment of pleural invasion isn't
continuously straightforward since tumors might abut the visceral
pleura while not invading it. recent studies have indicated
that elastic stains might be helpful and that in a few cases definitive
in a veryssessing whether or not true invasion of the pleura has
occurred. 399–403
if staging is predicated on pathologic analysis of lung tissue
and lns, there's typically a migration from lower- to
higher-stage disease (table 22. 6). clinical staging tends to
underestimate the extent of disease. it's vital to note
that the presence of enlarged lns on ct scanning isn't
a reliable indicator of metastatic disease at intervals those lns.
the specificity of this finding is merely 70%. if enlarged size is
taken as equivalent to metastatic disease, significant numbers
of patients are denied surgical therapy who would possibly otherwise
benefit. mediastinoscopy will aid within the staging of those
patients.
staging of tiny cell carcinoma sclc is clinically
staged as either limited or in depth disease. limited
stage typically refers to those tumors that are confined to
the chest together with supraclavicular lns however while not pleural
effusion. in depth stage refers to tumors that have metastasized
beyond the chest and that is equivalent to stage iv within the
nsclc staging system. combination of chemotherapy and
radiation is curative in a verypproximately 10% of limited stage
sclc patients however is rarely curative in in depth stage disease.
limited stage sclc thus is initially treated with
concurrent chemotherapy and radiation to the website of the
primary lesion. this regimen results in additional cures however may
not be well tolerated. patients with extensive-stage sclc
are initially treated with chemotherapy alone and radiation
therapy is reserved for either resistant or symptomatic disease.
it is that therefore vital for proper alternative of treatment
that sclc be properly staged each clinically and
pathologically.